





Quality and Safety Committee Action Log

			Open Actio	ns		
Action No.	Minute Ref.	Date	Agreed Action	Lead	Timescale	Status
1.	31/21	23.02.2021	Update on the additional 10 chemotherapy chairs at the day unit be provided Committee.	J Worthing	February 2022	A business case is being worked through by the Service Director for NPT Hospital and Singleton Hospital as part of Systematic Anti-Cancer Therapy (SACT) capacity, which links to the current unit (Singleton Hospital) or options around utilising NPT Hospital. Scheduled for February 2022, however will need to be taken through Management Board first.
2.	138/21, 127/21, 206/21, 245/21	27.07.2021 28.09.2021 26.10.2021	Older People's Charter to be revised along with the principles.	CW/ GH	January 2022	Meeting scheduled with Maggie Berry, Christine Williams and Gareth Howells on 2 nd December 2021. Update to be brought

						back to Quality and Safety Committee once the detail has been agreed.
3.	252/21	26.10.2021	Update report on the Welsh Health Circular quality and safety framework be received at future meeting.	PSD/ GH	February 2022	A substantive update to be received in February 2022.







			Closed Action	ons		
Action No.	Minute Ref.	Date	Agreed Action	Lead	Timescale	Status
4.	154/21	27.07.2021	Update report on the provision of the Cleft, Lip and Palate Service	КН	April 2022	Added to work programme for April 2022
5.	281/21	23.11.2021	Quality and Safety Governance Group - Update in the position of the recruitment process surrounding the Doctor for Safeguarding be detailed in December's QSGG report - SI learning to be shared with other service groups and details to be included in the next iteration of the QSGG report.	ND	December 2021	Completed.

6.	276/21	23.11.2021	Patient Experience Report	HL	January 2022	On agenda.
			 Actions surrounding the vaccine booking line issues to be reported in the next iteration of the patient experience report. 		2022	
			 A breakdown of what elements of communication are causing patient issues to be included in next iteration of the patient experience report. 			
			 Details of the SIs, including where, what, themes and actions be included in the next iteration of the report. 			
7.	312/21	21.12.2021	A substantive report on substance misuse to come to March's Quality and Safety Committee.	KR	March 2022	Added to work programme.
8.	317/21	21.12.2021	Confirmation to be provided to Martyn Waygood surrounding the reasons of the high referrals in Lymphoedema.	AC	December 2021	Completed. Response provided to Martyn Waygood and Steve Spill on 22/12/2021. "The reason for the high number of referrals for SBUHB is that the data includes the Bridgend catchment area. The SLA ends March 31st so will reduce by 1000 patients."

9.	313/21	21.12.2021	A report on clinical optimised patients from a quality and safety perspective be taken through January's Quality and Safety Committee.	IR	January 2022	Referred to Management Board on 26 th January 2022.
10.	279/21	23.11.2021	Steve Spill and Darren Griffiths to discuss financial options to strengthen management and use of controlled drugs.	DG	December 2021	A meeting is scheduled for 3 rd February 2022 to take this forward.







Relevant action's detailed within reports received to Quality and Safety Committee

	Open Actions					
Action No.	Minute Ref.	Date	Agreed Action	Lead	Timescale	Status
1.	153/21	-	Infection, Prevention and Control (IPC)	DD	-	-
			 Immunisation & vaccination. 			
			Action: Review by the Business Case			
			Group of the business case for a			
			sustainable Vaccination & Immunisation			
			Service to improve the uptake of			
			vaccinations against Influenza and other			
			preventable communicable diseases.			
			Target completion date: provisional			
			outcome anticipated by 31/01/22. Lead:			
			Matron Immunisation, Vaccination &			

	Assistant Director of Nursing. Impact:	
	Reducing preventable communicable	
	disease.	
	Action: There will be the development of an	
	action plan in line with the State of the	
	Nation 2021: Social Mobility and the	
	Pandemic July 2021 report. Target	
	completion date: To be agreed. Lead -	
	Executive Director of Nursing.	
	Working with Digital intelligence to	
	identify specification for the infection dashboard	
	QP Action: In collaboration with Digital	
	Intelligence team, establish the data feed	
	from LIMS, quality control and verify the	
	accuracy of the data accessed. Target	
	completion date: slippage due to COVID pressures to 31/03/22. Lead: Head of	
	Nursing Infection Prevention & Control, and	
	Business Intelligence Information Manager.	
	Impact: enable oversight of key indicators	
	at Ward, Specialty, and Delivery Unit and	
	Board level to enable early intervention and	
	improve patient safety.	
	 Antimicrobial initiatives – Secondary Care 	
	Action: Education and training sessions to	
	highlight the changes in the secondary care	

antimicrobial guidelines to minimise use of	
broad-spectrum antibiotics. Target	
Completion Date: Quarter 4, 2021/22.	
Lead: Consultant Antimicrobial	
Pharmacist. Impact: Decrease prescribing	
of broad-spectrum antibiotics that are high	
risk for <i>C. difficile</i> and antibiotic resistance.	
Antimicrobial initiatives – Primary Care	
Action: Baseline audits complete for	
cluster-based antibiotic quality	
improvement projects in Afan and City	
Health Clusters. Focus on UTI and skin	
and soft tissue infections. Project plan	
approved by PCCS HCAI/ AMR group and	
first PDSA cycles are underway. Target	
Completion Date: Quarter 4, 2021/22.	
Lead: Antimicrobial Pharmacy team.	
Impact: Identify priority targets for QI	
interventions to improve compliance to	
guidelines and overall volumes of	
prescribing within the GP practice.	
Antimicrobial initiatives – Health Board	
Action: A new Antimicrobial Stewardship	
Framework, governance structure and	
implementation plan has been agreed by	
the Clinical Outcome and Effectiveness	
Group. Reconvening the Antimicrobial	

Stewardship Group is critical to the
implementation of the Framework and work
to identify a new clinical chair is on-going.
Target completion date: Quarter 4,
2021/22. Impact: Improve governance
arrangements around antimicrobial
stewardship with the health board and
promote ownership and action at a service
delivery group and cluster/speciality level.
Clostridioides difficile infection
Action: Digital Intelligence are developing
an electronic investigation tool to allow MDT
input and improve scrutiny and identification
of themes by HB C. difficile Scrutiny Panel.
The electronic data collection tool is being
piloted to investigate new cases of C.
difficile infection identified in hospital.
Target completion date: draft of first stage
developed. Additional development
required, and date extended to Quarter 4,
2021/22. Lead: Quality Improvement
Matron IPC, Public Health Wales Infectious
Diseases/Microbiology Consultant. Impact:
More robust system to collate themes and
shared learning to improve the focus of
prevention and management initiatives,
leading to a reduction in <i>C. difficile</i> infection.

Bacteraemia improvement	
Action: Morriston Service Group's Medical	
Director has established a Consultant-led	
bacteraemia group, with multi-disciplinary	
representation, including a Public Health	
Wales Microbiologist, to review	
investigations of significant bloodstream	
infections and share lessons learned.	
Target completion date: group meeting	
dates set through 2021/22. Lead:	
Morriston Hospital Service Group	
Directors. Impact: reduction in significant	
bloodstream infections and share	
methodologies across the Health Board.	
Domestic staff recruitment	
Action: Recruitment process for additional	
cleaning staff progressing. Target	
completion date: Recruitment is ongoing	
process to meet possible shortfalls that	
occur through vacancies caused by	
retirement or staff leaving for alternative job	
opportunities. Lead: Support services	
manager. Impact: Increased domestic	
staffing to provide cleaning hours required.	
Decant (Quality Priority - built	
environment for management and	
prevention of HCAI)	
Action: The feasibility including a decant	
to the control of the	

facilities would enable work that is essential

for reducing infection risks from respiratory infections, including COVID-19, improving mechanical ventilation in inpatient areas to standards set in national, and WHO, guidance documents. Decant facilities are	
essential for enabling upgrade inpatient areas to increase single room accommodation, to meet standards set in national Health Building Note guidance. Target completion date: currently	
deferred due to COVID and service pressures. Lead: Assistant Director of Strategy Capital, Assistant Director of Strategy Estates.	